Clinical Trials Browser

Has results × Smoldering Multiple Myeloma × daratumumab × Clear all

NCT03236428 2026-03-27

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Phase 2 Active not recruiting

42 enrolled 8 charts

Smoldering Multiple Myeloma, Paraproteinemias